TACI antibody (PE)

Catalog No. ABIN2663249

This anti-TACI antibody is a Rat Monoclonal antibody detecting TACI in FACS and ICFC. Suitable for Human.

Quick Overview for TACI antibody (PE) (ABIN2663249)

Target: TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))

Reactivity: Human

Host: Rat

Clonality: Monoclonal

Conjugate: This TACI antibody is conjugated to PE

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Clone: 1A1

Product Details anti-TACI Antibody (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TACI

Target: TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))

Alternative Name: CD267

Background: TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.